Patents by Inventor Peter D. Williams
Peter D. Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11910856Abstract: Aspects herein are directed to an upper-body garment that facilitates upright sleeping. The garment includes an inner hood with a mesh elastic panel that is adapted to be positioned across the wearer's forehead helping to anchor the inner hood on to the wearer's head. The inner hood includes a low stretch or no stretch center panel. The center panel extends from the mesh elastic panel, down the center back of the inner hood, and further extends on to a back aspect of a torso portion of the garment where it forms a center portion of the back of the upper-body garment. Because the center panel has low stretch or no stretch, the wearer's head and neck are held in an upright or generally upright position when the inner hood is donned. The upper-body garment further includes a large volume outer hood positioned external to the inner hood.Type: GrantFiled: June 4, 2021Date of Patent: February 27, 2024Assignee: NIKE, Inc.Inventors: Gregory Dickson, Tobie D. Hatfield, Hee Ji, Daniel A. Judelson, Peter P. Williams, II
-
Publication number: 20200069691Abstract: The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.Type: ApplicationFiled: December 19, 2017Publication date: March 5, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Brian McKittrick, John P. Caldwell, John McCauley, Henry Vaccaro, Tin-Yau Chan, Hyunjin Kim, Elizabeth Smith, Liwu Hong, Tanweer Khan, Shihong Ying, Hongwu Wang, Peter D. Williams, Jae-Hun Kim, M. Brad Nolt, Maryann Caplen
-
Patent number: 10138255Abstract: The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.Type: GrantFiled: March 6, 2015Date of Patent: November 27, 2018Assignees: Merck Sharp & Dohme Corp., MSD R&D (China) Co., Ltd.Inventors: Peter D. Williams, John A. McCauley, Christopher J. Bungard, David Jonathan Bennett, Sherman T. Waddell, Gregori J. Morriello, Lehua Chang, Michael P. Dwyer, M. Katharine Holloway, Alejandro Crespo, Xin-Jie Chu, Catherine Wiscount, H. Marie Loughran, Jesse J. Manikowski, Jurgen Schulz, Kartik M. Keertikar, Bin Hu, Bin Zhong, Tao Ji
-
Patent number: 9994587Abstract: The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z1, Z2, V1, V2, V3, R6, R6A, and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HV protease, the inhibition of HV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: March 2, 2015Date of Patent: June 12, 2018Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.Inventors: John A. McCauley, David Jonathan Bennett, Christopher J. Bungard, Thomas J. Greshock, M. Katharine Holloway, Peter D. Williams, Christian Beaulieu, Sheldon Crane, Stephanie Lessard, Daniel Mckay, Carmela Molinaro, Oscar Miguel Moradei, Vijayasaradhi Sivalenka, Vouy Linh Truong, Satyanarayana Tummanapalli
-
Patent number: 9840478Abstract: The present invention is directed to piperazine derivatives, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.Type: GrantFiled: July 29, 2014Date of Patent: December 12, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Peter D. Williams, John A. McCauley, David Jonathan Bennett, Christopher J. Bungard, Lehua Chang, Michael P. Dwyer, M. Katharine Holloway, Kartik M. Keertikar, H. Marie Loughran, Jessie J. Manikowski, Gregori J. Morriello, Dong-Ming Shen, Edward C. Sherer, Jurgen Schultz, Sherman T. Waddell, Catherine M. Wiscount, Nicolas Zorn, Xin-Jie Chu, Satyanarayana Tummanapalli, Vijayasaradhi Sivalenka, Bin Hu, Tao Ji, Bin Zhong
-
Patent number: 9834526Abstract: The present invention is directed to 2,5,6-substituted morpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: December 17, 2014Date of Patent: December 5, 2017Assignees: MERCK SHARP & DOHME CORP., MERCK CANADA INC.Inventors: John A. McCauley, Christian Beaulieu, David Jonathan Bennett, Christopher J. Bungard, Sheldon Crane, Thomas J. Greshock, Katharine M. Holloway, Daniel McKay, Carmela Molinaro, Oscar Miguel Moradei, Satyanarayana Tummanapalli, Vouy Linh Truong, Peter D. Williams
-
Patent number: 9737545Abstract: The present invention is directed to 5-heteroarylmorpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: December 17, 2014Date of Patent: August 22, 2017Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.Inventors: John A. McCauley, Christian Beaulieu, David Jonathan Bennett, Christopher J. Bungard, Sheldon Crane, Thomas J. Greshock, Katharine M. Holloway, Helen Juteau, Daniel McKay, Carmela Molinaro, Oscar Miguel Moradei, Christian Nadeau, Daniel Simard, Satyanarayana Tummanapalli, Vouy Linh Truong, Karine M. Villeneuve, Peter D. Williams
-
Publication number: 20170217986Abstract: The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z1, Z2, V1, V2, V3, R6, R6A, and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HV protease, the inhibition of HV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: March 2, 2015Publication date: August 3, 2017Applicants: Merck Sharp & Dohme Corp., Merck Canada Inc.Inventors: John A. McCauley, David Jonathan Bennett, Christopher J. Bungard, Thomas J. Greshock, M. Katharine Holloway, Peter D. Williams, Christian Beaulieu, Sheldon Crane, Stephanie Lessard, Daniel Mckay, Carmela Molinaro, Oscar Miguel Moradei, Vijayasaradhi Sivalenka, Vouy Linh Truong, Satyanarayana Tummanapalli
-
Publication number: 20170073354Abstract: The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.Type: ApplicationFiled: March 6, 2015Publication date: March 16, 2017Applicants: Merck Sharp & Dohme Corp., MSD R&D (China) Co., Ltd.Inventors: Peter D. Williams, John A. McCauley, Christopher J. Bungard, David Jonathan Bennett, Sherman T. Waddell, Gregori J. Morriello, Lehua Chang, Michael P. Dwyer, M. Katharine Holloway, Alejandro Crespo, Xin-Jie Chu, Catherine Wiscount, H. Marie Loughran, Jesse J. Manikowski, Jurgen Schulz, Kartik M. Keertikar, Bin Hu, Bin Zhong, Tao Ji
-
Publication number: 20160311786Abstract: The present invention is directed to 2,5,6-substituted morpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: December 17, 2014Publication date: October 27, 2016Applicants: MERCK SHARP & DOHME CORP., MERCK CANADA INC.Inventors: John A. McCauley, Christian Beaulieu, David Jonathan Bennett, Christopher J. Bungard, Sheldon Crane, Thomas J. Greshock, Katharine M. Holloway, Daniel McKay, Carmela Molinaro, Oscar Miguel Moradei, Satyanarayana Tummanapalli, Vouy Linh Truong, Peter D. Williams
-
Publication number: 20160296527Abstract: The present invention is directed to 5-heteroarylmorpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: December 17, 2014Publication date: October 13, 2016Applicants: MERCK SHARP & DOHME CORP., MERCK CANADA INC.Inventors: John A. McCauley, Christian Beaulieu, David Jonathan Bennett, Christopher J. Bungard, Sheldon Crane, Thomas J. Greshock, Katharine M. Holloway, Helen Juteau, Daniel McKay, Carmela Molinaro, Oscar Miguel Moradei, Christian Nadeau, Daniel Simard, Satyanarayana Tummanapalli, Vouy Linh Truong, Karine M. Villeneuve, Peter D. Williams
-
Publication number: 20160159752Abstract: The present invention is directed to piperazine derivatives, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.Type: ApplicationFiled: July 29, 2014Publication date: June 9, 2016Applicants: Merck Sharp & Dohme Corp., MSD R&D (CHINA) CO., LTD.Inventors: Peter D. Williams, John A. McCauley, David Jonathan Bennett, Christopher J. Bungard, Lehua Chang, Michael P. Dwyer, M. Katharine Holloway, Kartik M. Keertikar, H. Marie Loughran, Jessie J. Manikowski, Gregori J. Morriello, Dong-Ming Shen, Edward C. Sherer, Jurgen Schultz, Sherman T. Waddell, Catherine M. Wiscount, Nicolas Zorn, Xin-Jie Chu, Satyanarayana Tummanapalli, Vijayasaradhi Sivalenka, Bin Hu, Tao Ji, Bin Zhong
-
Patent number: 9315475Abstract: The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: September 9, 2013Date of Patent: April 19, 2016Assignees: MERCK SHARP & DOHME CORP., MERCK CANADA INC.Inventors: Christian Beaulieu, David J. Bennett, Christopher J. Bungard, Ronald K. Chang, Sheldon Crane, Thomas J. Greshock, Li Hao, Kate Holloway, Jesse J. Manikowski, John A. McCauley, Daniel McKay, Carmela Molinaro, Oscar Miguel Moradei, Philippe G. Nantermet, Christian Nadeau, Satyanarayana Tummanapalli, William Shipe, Sanjay Kumar Singh, Vouy Linh Truong, Sivalenka Vijayasaradhi, Peter D. Williams, Catherine M. Wiscount
-
Patent number: 8871796Abstract: The invention encompasses a novel class of diaryl ether derivatives which inhibit the processing of APP by the putative ?-secretase while sparing Notch signaling pathway, and thus are useful in the treatment or prevention of Alzheimer's disease without the development of Notch inhibition mediated gastrointestinal issues. Pharmaceutical compositions and methods of use are also included.Type: GrantFiled: October 5, 2010Date of Patent: October 28, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: William Colby Brown, Jason Brubaker, Christian Fischer, Richard W. Heidebrecht, John T. Hendrix, Elizabeth H. Kelley, Rachel N. MacCoss, Joey L. Methot, Thomas Miller, Karin M. Otte, Phieng Siliphaivanh, Thomas Reger, Peter D. Williams, Catherine M. Wiscount
-
Publication number: 20140200197Abstract: The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: September 9, 2013Publication date: July 17, 2014Inventors: JOHN A. MCCAULEY, CHRISTIAN BEAULIEU, DAVID J. BENNETT, CHRISTOPHER J. BUNGARD, RONALD K. CHANG, SHELDON CRANE, THOMAS J. GRESHOCK, LI HAO, KATE HOLLOWAY, JESSE J. MANIKOWSKI, DANIEL MCKAY, CARMELA MOLINARO, OSCAR MIGUEL MORADEI, PHILIPPE G. NANTERMET, CHRISTIAN NADEAU, TUMMANAPALLI SATYANARAYANA, WILLIAM SHIPE, SANJAY KUMAR SINGH, VOUY LINH TRUONG, SIVALENKA VIJAYARADHI, PETER D. WILLIAMS, CATHERINE M. WISCOUNT
-
Publication number: 20130338141Abstract: Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein X1, X2, Y, R1A, R1B, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Processes for making compounds of Formula I and intermediates thereof are also described.Type: ApplicationFiled: August 19, 2013Publication date: December 19, 2013Inventors: Richard C. Isaacs, Wayne J. Thompson, Peter D. Williams, Dai-Shi Su, Shankar Venkatraman, Mark W. Embrey, Thorsten E. Fisher, John S. Wai, David C. Dubost, Richard G. Ball, Eric J. Choi, Tao Pei, Sarah L. Trice, Neil Campbell, Matthew Maddes, Peter E. Maligres, Michael Shevlin, Zhiguo Jake Song, Dietrich P. Steinhuebel, Neil A. Strotman, Jingjun Yin
-
Patent number: 8513234Abstract: Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein X1, X2, Y, R1A, R1B, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Processes for making compounds of Formula I and intermediates thereof are also described.Type: GrantFiled: October 2, 2009Date of Patent: August 20, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Richard C. A. Isaacs, Wayne J. Thompson, Peter D. Williams, Dai-Shi Su, Shankar Venkatraman, Mark W. Embrey, Thorsten E. Fisher, John S. Wai, David C. Dubost, Richard G. Ball, Eric J. Choi, Tao Pei, Sarah L. Trice, Neil Campbell, Matthew Maddess, Peter E. Maligres, Michael Shevlin, Zhiguo Jake Song, Dietrich P. Steinhuebel, Neil A. Strotman, Jingjun Yin
-
Publication number: 20130053386Abstract: The invention encompasses a novel class of diaryl ether derivatives which inhibit the processing of APP by the putative ?-secretase while sparing Notch signaling pathway, and thus are useful in the treatment or prevention of Alzheimer's disease without the development of Notch inhibition mediated gastrointestinal issues. Pharmaceutical compositions and methods of use are also included.Type: ApplicationFiled: October 5, 2010Publication date: February 28, 2013Inventors: William Colby Brown, Richard W. Heidebrecht, Jason Brubaker, Christian Fischer, John T. Hendrix, Elizabeth H. Kelley, Rachel N. MacCoss, Joey L. Methot, Thomas Miller, Karin M. Otte, Phieng Siliphaivanh, Thomas Reger, Peter D. Williams, Catherine M. Wiscount
-
Publication number: 20120022045Abstract: Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: the asterisk * in Q denotes the point of attachment to the rest of the compound; and n, L1, L2, X1, X2, ?3, Y, Z, R1, R2 and R3 are defined herein. The N compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: January 25, 2010Publication date: January 26, 2012Inventors: Shankar Venkatraman, John S. Wai, Wayne Thompson, Boyoung Kim, Richard C.A. Isaacs, H. Marie Loughran, Dai-Shi Su, John Lim, Mark W. Embrey, Peter D. Williams
-
Patent number: 7820680Abstract: Bicyclic uracils and related compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the compounds are of Formula I: wherein a, b, Y, R1, R2, R3 and R4 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: March 4, 2005Date of Patent: October 26, 2010Assignee: Merck & Co., Inc.Inventors: Peter D. Williams, John S. Wai, Mark W. Embrey, Donnette D. Staas, Linghang Zhuang